Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Saturday, April 9, 2011

Abstract from Nigel Manning : B2 responsiveness in a TMAU patient

Abstract from Nigel Manning : B2 responsiveness in a TMAU patient

This is an abstract paper (pre-publication) done by Nigel Manning, Principal Clinical Scientist, Dept of Clinical Chemistry, Sheffield Children's Hospital, and others at the same hospital.

It is a case study of a patient with homocystinuria who was on betaine therapy and then over around 10 years started to have a 'fish odor' complaint. The patient was found to have the 158-308 DNA combo that can cause mild genetic deficiency of FMO3 enzyme. The urine sample had very high levels of TMA (392 mmols/mol).

It was decided to try B2 therapy and the TMA levels were checked 5 times over 240 days. In the graph, it can be seen the TMA levels dropped dramatically, eventually being 17 mmols/mol. This is still above Sheffield's normal saturation level of 10.8, but a vast improvement. Also, the % of TMA converted to TMAO  went from 7% to 83%, but this could be due to reducing the level of TMA-producing bacteria alone.

Presumably this study was carried out because people with homocystinuria have to take high doses of betaine. Betaine is known to cause high levels of dimethylglycine, which is recorded as causing a fish odor.

The TMA levels dropped, but we are told the TMAO levels did not conversely increase, rather, the overall TMA + TMAO level dropped. So it cannot be ruled out that the gut infection was reduced rather than B2 causing increase in TMAO function ?? Since high betaine levels are used for another disorder in this study, this suggests perhaps FMO3 function was increased. There still remains a few questions about B2 responsiveness that need to be checked.

All the same, it is an interesting study and B2 responsiveness would make a great study for TMAU. In this study, they used 100mg B2 twice a day.


Post a Comment